Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).

Wien Klin Wochenschr · 2022 · PMC9022736 · PMID 35449467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For PaxlovidTM, a combination of PF-07321332 (nirmatrelvir) and ritonavir, EMA has started a rolling review process after a prospective study, showing a highly significant benefit in the combined endpoint of hospitalization or death at day 28, which was met by 1% vs. 7%.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.